An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/11/2019 |
| Start Date: | October 2014 |
| End Date: | December 2019 |
Patients are asked to participate in this study if they have been diagnosed with a thoracic
carcinoma which includes lung cancer and have a gene mutation (alteration in the body's
genetic instructions) and after undergoing treatment the cancer has come back, progressed, or
shown a partial response on standard treatment.
carcinoma which includes lung cancer and have a gene mutation (alteration in the body's
genetic instructions) and after undergoing treatment the cancer has come back, progressed, or
shown a partial response on standard treatment.
In order to improve the treatment outcome for thoracic carcinomas after they become resistant
to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for
genomic analysis to identify novel somatic changes in critical genes and gene pathways that
can potentially be targeted with therapy. The study team is also creating patient-derived
xenografts to test drug efficacy and optimize personalized therapy for each patient.
to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for
genomic analysis to identify novel somatic changes in critical genes and gene pathways that
can potentially be targeted with therapy. The study team is also creating patient-derived
xenografts to test drug efficacy and optimize personalized therapy for each patient.
Inclusion Criteria:
- 18 years or older
- Thoracic carcinoma tumors are positive for any targetable genetic alterations
- Have shown partial or no response, progression or recurrence while on or after gene
targeted therapy by CT/PET scan
- Tumor is accessible for biopsy or surgery
- Expected life is 6 months or longer.
Exclusion Criteria:
- < 18 years
- Not able to communicate in English
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Jin Jen, MD, PhD
Phone: 507-266-0887
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
